Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.3389/fmicb.2018.01895 http://hdl.handle.net/11449/166280 |
Resumo: | There is an urgent need to treat tuberculosis (TB) quickly, effectively and without side effects. Mycobacterium tuberculosis (Mtb), the causative organism of TB, can survive for long periods of time within macrophages and dendritic cells and these intracellular bacilli are difficult to eliminate with current drug regimens. It is well established that Mtb responds differentially to drug treatment depending on its extracellular and intracellular location and replicative state. In this study, we isolated and cultured lung derived dendritic cells to be used as a screening system for drug efficacy against intracellular mycobacteria. Using mono- or combination drug treatments, we studied the action of spectinamide-1599 and pyrazinamide (antibiotics targeting slow-growing bacilli) in killing bacilli located within lung derived dendritic cells. Furthermore, because IFN-gamma is an essential cytokine produced in response to Mtb infection and present during TB chemotherapy, we also assessed the efficacy of these drugs in the presence and absence of IFN-gamma. Our results demonstrated that monotherapy with either spectinamide-1599 or pyrazinamide can reduce the intracellular bacterial burden by more than 99.9%. Even more impressive is that when TB infected lung derived dendritic cells are treated with spectinamide-1599 and pyrazinamide in combination with IFN-gamma a strong synergistic effect was observed, which reduced the intracellular burden below the limit of detection. We concluded that IFN-gamma activation of lung derived dendritic cells is essential for synergy between spectinamide-1599 and pyrazinamide. |
id |
UNSP_7c9040f5f091963b39dba14253a03ae7 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/166280 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosisspectinamidesMycobacterium-tuberculosisintracellularlungdendritic cellsGM-CSFpyrazinamideinterferonThere is an urgent need to treat tuberculosis (TB) quickly, effectively and without side effects. Mycobacterium tuberculosis (Mtb), the causative organism of TB, can survive for long periods of time within macrophages and dendritic cells and these intracellular bacilli are difficult to eliminate with current drug regimens. It is well established that Mtb responds differentially to drug treatment depending on its extracellular and intracellular location and replicative state. In this study, we isolated and cultured lung derived dendritic cells to be used as a screening system for drug efficacy against intracellular mycobacteria. Using mono- or combination drug treatments, we studied the action of spectinamide-1599 and pyrazinamide (antibiotics targeting slow-growing bacilli) in killing bacilli located within lung derived dendritic cells. Furthermore, because IFN-gamma is an essential cytokine produced in response to Mtb infection and present during TB chemotherapy, we also assessed the efficacy of these drugs in the presence and absence of IFN-gamma. Our results demonstrated that monotherapy with either spectinamide-1599 or pyrazinamide can reduce the intracellular bacterial burden by more than 99.9%. Even more impressive is that when TB infected lung derived dendritic cells are treated with spectinamide-1599 and pyrazinamide in combination with IFN-gamma a strong synergistic effect was observed, which reduced the intracellular burden below the limit of detection. We concluded that IFN-gamma activation of lung derived dendritic cells is essential for synergy between spectinamide-1599 and pyrazinamide.National Institute of Allergy and Infectious DiseasesOffice of the Director, National Institutes of HealthFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USASao Paulo State Univ, Sch Pharmaceut Sci, Sao Paulo, BrazilUniv Tennessee, Coll Pharm, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN USAUniv N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USARTI Int, Discovery Sci & Technol, Durham, NC USASao Paulo State Univ, Sch Pharmaceut Sci, Sao Paulo, BrazilNational Institute of Allergy and Infectious Diseases: R01AI120670Office of the Director, National Institutes of Health: S10OD016226FAPESP: 2016/20622-4Frontiers Media SaColorado State UnivUniversidade Estadual Paulista (Unesp)Univ TennesseeUniv N CarolinaRTI IntSantos, Karen [UNESP]Lukka, Pradeep B.Grzegorzewicz, AnneJackson, MaryTrivedi, AshitPavan, Fernando [UNESP]Chorilli, Marius [UNESP]Braunstein, MiriamHickey, AnthonyMeibohm, BerndGonzalez-Juarrero, Mercedes2018-11-30T00:42:41Z2018-11-30T00:42:41Z2018-08-21info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article11application/pdfhttp://dx.doi.org/10.3389/fmicb.2018.01895Frontiers In Microbiology. Lausanne: Frontiers Media Sa, v. 9, 11 p., 2018.1664-302Xhttp://hdl.handle.net/11449/16628010.3389/fmicb.2018.01895WOS:000442209500001WOS000442209500001.pdfWeb of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengFrontiers In Microbiologyinfo:eu-repo/semantics/openAccess2024-06-24T13:44:48Zoai:repositorio.unesp.br:11449/166280Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T13:33:41.282447Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis |
title |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis |
spellingShingle |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis Santos, Karen [UNESP] spectinamides Mycobacterium-tuberculosis intracellular lung dendritic cells GM-CSF pyrazinamide interferon |
title_short |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis |
title_full |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis |
title_fullStr |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis |
title_full_unstemmed |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis |
title_sort |
Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis |
author |
Santos, Karen [UNESP] |
author_facet |
Santos, Karen [UNESP] Lukka, Pradeep B. Grzegorzewicz, Anne Jackson, Mary Trivedi, Ashit Pavan, Fernando [UNESP] Chorilli, Marius [UNESP] Braunstein, Miriam Hickey, Anthony Meibohm, Bernd Gonzalez-Juarrero, Mercedes |
author_role |
author |
author2 |
Lukka, Pradeep B. Grzegorzewicz, Anne Jackson, Mary Trivedi, Ashit Pavan, Fernando [UNESP] Chorilli, Marius [UNESP] Braunstein, Miriam Hickey, Anthony Meibohm, Bernd Gonzalez-Juarrero, Mercedes |
author2_role |
author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Colorado State Univ Universidade Estadual Paulista (Unesp) Univ Tennessee Univ N Carolina RTI Int |
dc.contributor.author.fl_str_mv |
Santos, Karen [UNESP] Lukka, Pradeep B. Grzegorzewicz, Anne Jackson, Mary Trivedi, Ashit Pavan, Fernando [UNESP] Chorilli, Marius [UNESP] Braunstein, Miriam Hickey, Anthony Meibohm, Bernd Gonzalez-Juarrero, Mercedes |
dc.subject.por.fl_str_mv |
spectinamides Mycobacterium-tuberculosis intracellular lung dendritic cells GM-CSF pyrazinamide interferon |
topic |
spectinamides Mycobacterium-tuberculosis intracellular lung dendritic cells GM-CSF pyrazinamide interferon |
description |
There is an urgent need to treat tuberculosis (TB) quickly, effectively and without side effects. Mycobacterium tuberculosis (Mtb), the causative organism of TB, can survive for long periods of time within macrophages and dendritic cells and these intracellular bacilli are difficult to eliminate with current drug regimens. It is well established that Mtb responds differentially to drug treatment depending on its extracellular and intracellular location and replicative state. In this study, we isolated and cultured lung derived dendritic cells to be used as a screening system for drug efficacy against intracellular mycobacteria. Using mono- or combination drug treatments, we studied the action of spectinamide-1599 and pyrazinamide (antibiotics targeting slow-growing bacilli) in killing bacilli located within lung derived dendritic cells. Furthermore, because IFN-gamma is an essential cytokine produced in response to Mtb infection and present during TB chemotherapy, we also assessed the efficacy of these drugs in the presence and absence of IFN-gamma. Our results demonstrated that monotherapy with either spectinamide-1599 or pyrazinamide can reduce the intracellular bacterial burden by more than 99.9%. Even more impressive is that when TB infected lung derived dendritic cells are treated with spectinamide-1599 and pyrazinamide in combination with IFN-gamma a strong synergistic effect was observed, which reduced the intracellular burden below the limit of detection. We concluded that IFN-gamma activation of lung derived dendritic cells is essential for synergy between spectinamide-1599 and pyrazinamide. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-11-30T00:42:41Z 2018-11-30T00:42:41Z 2018-08-21 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.3389/fmicb.2018.01895 Frontiers In Microbiology. Lausanne: Frontiers Media Sa, v. 9, 11 p., 2018. 1664-302X http://hdl.handle.net/11449/166280 10.3389/fmicb.2018.01895 WOS:000442209500001 WOS000442209500001.pdf |
url |
http://dx.doi.org/10.3389/fmicb.2018.01895 http://hdl.handle.net/11449/166280 |
identifier_str_mv |
Frontiers In Microbiology. Lausanne: Frontiers Media Sa, v. 9, 11 p., 2018. 1664-302X 10.3389/fmicb.2018.01895 WOS:000442209500001 WOS000442209500001.pdf |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Frontiers In Microbiology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
11 application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media Sa |
publisher.none.fl_str_mv |
Frontiers Media Sa |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128247404167168 |